SCHEMBL1046887

SCHEMBL1046887

CC(C)(C)CNCC(=O)N[C@H]1CC[C@H](Nc2cc(-c3c[nH]c4ncccc34)cc(Cl)n2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 0.63
GSK3B P49841 11/20 0.63
ROCK2 O75116 13/20 0.59
PRKACA P17612 13/20 0.59
CDK2 P24941 12/20 0.59
HIPK2 Q9H2X6 12/20 0.59
DYRK1A Q13627 11/20 0.59
PIM1 P11309 11/20 0.59
CLK4 Q9HAZ1 10/20 0.59
CLK2 P49760 10/20 0.59
CDK5 Q00535 10/20 0.59
STK17A Q9UEE5 10/20 0.59
CDK9 P50750 10/20 0.59
MAP4K4 O95819 10/20 0.59
DAPK3 O43293 9/20 0.59
PRKX P51817 9/20 0.59
PKN2 Q16513 9/20 0.59
MINK1 Q8N4C8 9/20 0.59
MAP4K5 Q9Y4K4 9/20 0.59
CDK8 P49336 8/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049066 0.89 CDC7 (0.73) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1045466 0.89 CDC7 (0.65) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1051218 0.86 CDC7 (0.64) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1050206 0.86 CDC7 (0.74) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1050438 0.86 CDC7 (0.66) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1041849 0.86 CDC7 (0.68) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1046745 0.86 CDC7 (0.44) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL14905752 0.85 CDC7 (0.73) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1045476 0.85 CDC7 (0.74) CDC7GSK3BROCK2PRKACACDK2
SCHEMBL1050650 0.84 CDC7 (0.68) CDC7GSK3BROCK2PRKACACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP claimed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US claimed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US claimed
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885GSK3B 442/4885ROCK2 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.